Lexaria claims technology could reduce GLP-1 drug side effects

Lexaria Bioscience Corp. (NASDAQ: LEXX) stated its DehydraTECH technology could address side effects in GLP-1 drugs used for weight loss and diabetes treatment, according to a company press release.

The GLP-1 pharmaceutical sector generated $53.5 billion in revenue in 2024 and is projected to reach $156 billion by 2030, the company said. Despite growth, discontinuation rates remain high, with studies showing 47% to 64% of type 2 diabetes patients stopping GLP-1 use within one to two years primarily due to gastrointestinal side effects including nausea, vomiting, diarrhea and constipation.

Lexaria reported that data from four Novo Nordisk studies involving 4,218 participants showed 75.7% experienced gastrointestinal adverse events when using semaglutide-based treatments. Martin Holst Lange, executive vice president at Novo Nordisk, acknowledged at a June investor event that the company seeks to improve the gastrointestinal side effect profile of its treatments.

The company claims its DehydraTECH technology has shown potential to reduce side effects in human clinical testing for three leading GLP-1 drugs: tirzepatide from Eli Lilly, and semaglutide and liraglutide from Novo Nordisk. Lexaria said it entered a material transfer agreement with an unnamed pharmaceutical company in September 2024 to evaluate its technology.

DehydraTECH is described as a drug delivery platform designed to improve oral absorption of various medications. Lexaria holds 50 granted patents with additional applications pending worldwide for the technology.

You May Also Be Interested In

• Barclays Downgrades Travelers (TRV) to Underweight
• Expensify completes $7.3 million tender offer for 6.1 million shares
• Wolfe Research: Ball may see volume boost from World Cup and energy drinks